Participación comunitaria y procesos de comunicación en la implementación de programas de reasentamiento de familias dentro del contexto del desarrollo urbano en Barranquilla (Colombia)

Planning processes of development and growth of the city of Barranquilla have required the relocation of the population living in areas of intervention actions. As part of the implementation of the New Management Plan Territorial (POT), the city plans to revitalize an area around the Magdalena River with a view to improving the quality of life of citizens and to increase competitiveness of the city. The revitalization project is known as project “La Loma “. Under the current Land Use Plan of Barranquilla (POT), the urban development project “La Loma” includes, among other activities, the transfer of a large number of people currently living in this area. For this reason, this article aims to review the current POT and documents from City Council and the Mayor’s office associated with the POT and “La Loma” project, in order to identify and analyze the component of community participation and communication related to the implementation of this project. The results of the documents revealed the presence of regulatory elements associated with community participation. The results also showed potentially useful spaces for the implementation of inclusive communication processes. Therefore, this article proposes a guide for the formulation of a strategic communication plan with a focus on participatory communication and dialogue facilitator to be used during the execution of urban projects that include the relocation of families. © 2016, Universidad del Norte. All rights reserved

RICORS2040 : The need for collaborative research in chronic kidney disease

Chronic kidney disease (CKD) is a silent and poorly known killer. The current concept of CKD is relatively young and uptake by the public, physicians and health authorities is not widespread. Physicians still confuse CKD with chronic kidney insufficiency or failure. For the wider public and health authorities, CKD evokes kidney replacement therapy (KRT). In Spain, the prevalence of KRT is 0.13%. Thus health authorities may consider CKD a non-issue: very few persons eventually need KRT and, for those in whom kidneys fail, the problem is 'solved' by dialysis or kidney transplantation. However, KRT is the tip of the iceberg in the burden of CKD. The main burden of CKD is accelerated ageing and premature death. The cut-off points for kidney function and kidney damage indexes that define CKD also mark an increased risk for all-cause premature death. CKD is the most prevalent risk factor for lethal coronavirus disease 2019 (COVID-19) and the factor that most increases the risk of death in COVID-19, after old age. Men and women undergoing KRT still have an annual mortality that is 10- to 100-fold higher than similar-age peers, and life expectancy is shortened by ~40 years for young persons on dialysis and by 15 years for young persons with a functioning kidney graft. CKD is expected to become the fifth greatest global cause of death by 2040 and the second greatest cause of death in Spain before the end of the century, a time when one in four Spaniards will have CKD. However, by 2022, CKD will become the only top-15 global predicted cause of death that is not supported by a dedicated well-funded Centres for Biomedical Research (CIBER) network structure in Spain. Realizing the underestimation of the CKD burden of disease by health authorities, the Decade of the Kidney initiative for 2020-2030 was launched by the American Association of Kidney Patients and the European Kidney Health Alliance. Leading Spanish kidney researchers grouped in the kidney collaborative research network Red de Investigación Renal have now applied for the Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS) call for collaborative research in Spain with the support of the Spanish Society of Nephrology, Federación Nacional de Asociaciones para la Lucha Contra las Enfermedades del Riñón and ONT: RICORS2040 aims to prevent the dire predictions for the global 2040 burden of CKD from becoming true

On the mechanisms governing gas penetration into a tokamak plasma during a massive gas injection

A new 1D radial fluid code, IMAGINE, is used to simulate the penetration of gas into a tokamak plasma during a massive gas injection (MGI). The main result is that the gas is in general strongly braked as it reaches the plasma, due to mechanisms related to charge exchange and (to a smaller extent) recombination. As a result, only a fraction of the gas penetrates into the plasma. Also, a shock wave is created in the gas which propagates away from the plasma, braking and compressing the incoming gas. Simulation results are quantitatively consistent, at least in terms of orders of magnitude, with experimental data for a D 2 MGI into a JET Ohmic plasma. Simulations of MGI into the background plasma surrounding a runaway electron beam show that if the background electron density is too high, the gas may not penetrate, suggesting a possible explanation for the recent results of Reux et al in JET (2015 Nucl. Fusion 55 093013)

Measurements of differential production cross sections for a Z boson in association with jets in pp collisions at root s=8 TeV

Peer reviewe

Search for the associated production of the Higgs boson with a top-quark pair

A search for the standard model Higgs boson produced in association with a top-quark pair t t ¯ H (tt¯H) is presented, using data samples corresponding to integrated luminosities of up to 5.1 fb −1 and 19.7 fb −1 collected in pp collisions at center-of-mass energies of 7 TeV and 8 TeV respectively. The search is based on the following signatures of the Higgs boson decay: H → hadrons, H → photons, and H → leptons. The results are characterized by an observed t t ¯ H tt¯H signal strength relative to the standard model cross section, μ = σ/σ SM ,under the assumption that the Higgs boson decays as expected in the standard model. The best fit value is μ = 2.8 ± 1.0 for a Higgs boson mass of 125.6 GeV

Measurement of prompt Jψ\psi pair production in pp collisions at \sqrt s = 7 Tev

Production of prompt J/ ψ meson pairs in proton-proton collisions at s s√ = 7 TeV is measured with the CMS experiment at the LHC in a data sample corresponding to an integrated luminosity of about 4.7 fb −1 . The two J/ ψ mesons are fully reconstructed via their decays into μ + μ − pairs. This observation provides for the first time access to the high-transverse-momentum region of J/ ψ pair production where model predictions are not yet established. The total and differential cross sections are measured in a phase space defined by the individual J/ ψ transverse momentum ( p T J/ ψ ) and rapidity (| y J/ ψ |): | y J/ ψ | 6.5 GeV/ c ; 1.2 4.5 GeV/ c . The total cross section, assuming unpolarized prompt J/ ψ pair production is 1.49 ± 0.07 (stat) ±0.13 (syst) nb. Different assumptions about the J/ ψ polarization imply modifications to the cross section ranging from −31% to +27%

Charged-particle nuclear modification factors in PbPb and pPb collisions at √=sNN=5.02 TeV

The spectra of charged particles produced within the pseudorapidity window |η| < 1 at √ sNN = 5.02 TeV are measured using 404 µb −1 of PbPb and 27.4 pb−1 of pp data collected by the CMS detector at the LHC in 2015. The spectra are presented over the transverse momentum ranges spanning 0.5 < pT < 400 GeV in pp and 0.7 < pT < 400 GeV in PbPb collisions. The corresponding nuclear modification factor, RAA, is measured in bins of collision centrality. The RAA in the 5% most central collisions shows a maximal suppression by a factor of 7–8 in the pT region of 6–9 GeV. This dip is followed by an increase, which continues up to the highest pT measured, and approaches unity in the vicinity of pT = 200 GeV. The RAA is compared to theoretical predictions and earlier experimental results at lower collision energies. The newly measured pp spectrum is combined with the pPb spectrum previously published by the CMS collaboration to construct the pPb nuclear modification factor, RpA, up to 120 GeV. For pT > 20 GeV, RpA exhibits weak momentum dependence and shows a moderate enhancement above unity

Effects Of Morin On Snake Venom Phospholipase A2 (pla 2)

Flavonoids are potent anti-inflammatory compounds isolated from several plant extracts, and have been used experimentally against inflammatory processes. In this work, a PLA2 isolated from the Crotalus durissus cascavella venom and rat paw oedema were used as a model to study the effect of flavonoids on PLA2. We observed that a treatment of PLA2 with morin induces several modifications in the aromatic amino acids, with accompanying changes in its amino acid composition. In addition, results from circular dichroism spectroscopy and UV scanning revealed important structural modifications. Concomitantly, a considerable decrease in the enzymatic and antibacterial activities was observed, even though anti-inflammatory and neurotoxic activities were not affected. These apparent controversial results may be an indication that PLA2 possess a second pharmacological site which does not affect or depend on the enzymatic activity. © 2005 Elsevier Ltd. All rights reserved.467751758Bors, W., Heller, W., Michel, C., Saran, M., Flavonoids as anti-oxidants: Determination of radical-scavenging efficiencies (1990) Method. Enzymol., 186, pp. 343-355Cao, G., Verdon, C., Wu, A.H.B., Wang, H., Prior RL-Automated oxygen radical absorbance capacity assay using the COBAS FARA II (1995) Clin. Chem., 41, pp. 1738-1744Cao, G., Sofie, E., Prior, R.L., Antioxidant and prooxidant behavior of flavonoids: Structure-activity relationships (1997) Free Radic. Biol. Med., 22, pp. 749-760Chandra, V., Jasti, J., Kaur, P., Betzel, C., Srinivasan, A., Singh, T.P., First structural evidence of a specific inhibition of phospholipase A2 by α-Tocopherol (Vitamin E) and its implication in inflammation: Crystal structure of the complex formed between phospholipase A2 and α-Tocopherol at 1.8 Å resolution (2002) J. Mol. Biol., 320, pp. 215-222Di Carlo, G., Mascolo, N., Izzo, A.A., Capasso, F., Flavonoids: Old and new aspects of class of natural therapeutic drugs (1999) Life Sci., 65, pp. 337-353Fang, S.-H., Hou, Y.-C., Chang, W.-C., Hsiu, S.-L., Lee Chao, P.-D., Chiang, B.-L., Morin sulfates/ glucuronides exert anti-inflammatory activity on activated macrophages and decreased the incidence of septic shock (2003) Life Sci., 74 (6), pp. 743-756Fawzy, A.A., Vishwanath, B.S., Franson, R.C., Inhibition of human non-pancreatic phospholipase A2 by retinoids and flavonoids. Mechanism of action (1988) Agents Actions, 25 (3-4), pp. 394-400Gil, B., Sanz, J., Terencio, M.C., Gunasegaran, R., Payá, M., Alcazar, M.J., Morelloflavone, a novel biflavonoid inhibitor of human secretory phospholipase A2 with anti-inflammatory activity (1997) Biochem. Pharmacol., 53, pp. 733-743Ginsborg, B.L., Warriner, J., The isolated chick biventer cervicis nerve-muscle preparation (1960) Br. Pharm. Chemother., 15, pp. 410-421Harborne, J.B., (1988) The Flavonoids: Advances in Research, , Chapman & Hall LondonHodnick, W.F., Duval, D.L., Pardini, R.S., Inhibition of mithocondrial respiration and cyaned stimulated generation of reactive oxygen species by selected flavonoids (1994) Biochem. Pharmacol., 47 (3), pp. 573-580Holzer, M., MacKessy, S.P., An aqueous endpoint assay of snake venom phospholipase A2 (1996) Toxicon, 34 (10), pp. 1149-1155Kitagawa, S., Sakamoto, H., Tano, H., Inhibitory effect of flavonoids on free radical-induced hemolysis and ther oxidative effect on hemoglobin (2004) Chem. Pharm. Bull., 52 (8), pp. 999-1001Koduri, R.S., Grönrooss, J.O., Laine, V.J.O., Calvez, C.L., Lambeau, G., Nevelainen, T.J., Gelb, M.H., Bactericidal properties of human and murine groups I, II, V, X and XII secreted phospholipases A2 (2002) J. Biol. Chem., 277 (8), pp. 5849-5857Lindahl, M., Tagesson, C., Flavonoids as phospholipase A2 inhibitors: Importance of their structure for selective inhibition of group II phospholipase A2 (1997) Inflammation, 21 (3), pp. 347-356Middleton Jr., E., Drzewiecki, G., Flavonoid inhibition of human basophile histamine release stimulated by various agents (1984) Biochem. Pharmacol., 33, pp. 3333-3338Murakami, M., Shimbara, S., Kambe, T., Kuwata, H., Winstead, M.V., Tishifield, J.A., Kudo, I., The functions of five distinct mammalian phospholipase A2s in regulating arachidonic acid release (1998) J. Biol. Chem., 273 (23), pp. 14411-14423Rice-Evans, C.A., Miller, N.J., Paganga, G., Structure antioxidant activity relationships of flavonoids and phenolic acids (1996) Free Radic. Biol. Med., 20, pp. 933-956Rotelli, A.E., Guardia, T., Juarez, A.O., De La Rocha, N.E., Pelzer, L.E., Comparative study of flavonoids in experimental models of inflammation (2003) Pharmacol. Res., 48, pp. 601-606Schagger, H., Von Jagow, G., Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa (1987) Anal. Biochem., 166 (2), pp. 368-379Takeda, A.A., Dos Santos, J.I., Marcussi, S., Silveira, L.B., Soares, A.M., Fontes, M.R., Crystallization and preliminary X-ray diffraction analysis of an acidic phospholipase A(2) complexed with p-bromophenacyl bromide and alpha-tocopherol inhibitors at 1.9- and 1.45-A resolution (2004) Biochim. Biophys. Acta., (1-2), pp. 281-284Teixeira, C.F., Landucci, E.C., Antunes, E., Chacur, M., Cury, Y., Inflammatory effects of snake venom myotoxic phospholipases A2 (2003) Toxicon, 42 (8), pp. 947-962Toyama, M.H., De Oliveira, D.G., Beriam, L.O., Novello, J.C., Rodrigues-Simioni, L., Marangoni, S., Structural, enzymatic and biological properties of new PLA(2) isoform from Crotalus durissus terrificus venom (2003) Toxicon, 41 (8), pp. 1033-1038Valentin, E., Lambeau, G., Increasing molecular diversity of secreted phospholipases A2 and their receptor and binding proteins (2000) Biochim. Biophys. Acta, 1488, pp. 59-70Vishwanath, B.S., Fawzy, A.A., Franson, R.C., Edema-inducing activity of phospholipase A2 purified from synovial fluid and inhibition by aristolochic acid (1988) Inflammation, 12 (6), pp. 549-561Williams, C.N., Honet, J.R.S., Harborne, J.B., Greenham, J., Eeagles, J.A., Biologically active lipophilic flavonols from Tanacetum parthenium (1995) Phytochemistry, 38, pp. 267-270Xu, H., Ziegelin, G., Schroder, W., Frank, J., Ayora, S., Alonso, J.C., Lanka, E., Saenger, W., Flavones inhibit the hexameric replicative helicase RepA (2001) Nucleic Acids Res., 29 (24), pp. 5058-5066Zhao, H., Tang, L., Wang, X.-Q., Zhou, Y., Lin, Z., Structural of a snake venom phospholipase A2 modified by p-Bromophenacyl bromide (1998) Toxicon, 36 (6), pp. 875-88

Effects of morin on snake venom phospholipase A(2) (PLA(2))

FAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOFlavonoids are potent anti-inflammatory compounds isolated from several plant extracts, and have been used experimentally against inflammatory processes. In this work, a PLA(2) isolated from the Crotalus durissus cascavella venom and rat paw oedema were used as a model to. study the effect of flavonoids on PLA(2). We observed that a treatment of PLA(2) with morin induces several modifications in the aromatic amino acids, with accompanying changes in its amino acid composition. In addition, results from circular dichroism spectroscopy and UV scanning revealed important structural modifications. Concomitantly, a considerable decrease in the enzymatic and antibacterial activities was observed, even though anti-inflammatory and neurotoxic activities were not affected. These apparent controversial results may be an indication that PLA(2) possess a second pharmacological site which does not affect or depend on the enzymatic activityPergamon Press467751758FAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULOFAPESP - FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE SÃO PAULO04/00040-3Oxfor